Actinium Pharmaceuticals ATNM
$
Relative Strength Index (RSI)
- The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. It is typically used to identify overbought or oversold conditions in financial markets.
- The RSI is calculated using the following formula:
RSI = 100 - (100 / (1 + RS))
Where RS is the ratio of the average gains to the average losses over a specified period.
- The default time period used is 14 days.
- RSI values range between 0 and 100.
RSI values above 70 are considered overbought (indicating a potentially opportune time to sell)
RSI values below 30 are considered oversold (indicating a potentially opportune time to buy)
RSI is not a perfect indicator and should be used in conjunction with other technical analysis tools, this is for informational purposes only and is not a substitute for professional financial advice.
About
Business overview of Actinium Pharmaceuticals (ATNM)
Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of radiotherapies for patients with cancers lacking effective treatment options. The company's proprietary technology platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest to kill those cells safely and effectively. Its product candidates are Iomab-B, an antibody-drug construct containing iodine 131 (I-131), used for hematopoietic stem cells transplantation in various indications and Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), currently in human clinical trials for acute myeloid leukemia.
Key Insights
Critical company metrics and information
Latest Closing Price
$1.14Market Cap
$35.56 MillionPrice-Earnings Ratio
-3.08Total Outstanding Shares
31.20 Million SharesTotal Employees
49Dividend
No dividendIPO Date
July 19, 2007SIC Description
Pharmaceutical PreparationsPrimary Exchange
American Stock ExchangeType
Common StockHeadquarters
100 park ave., 23rd floor, New york, NY, 10017Homepage
https://www.actiniumpharma.com
Historical Stock Splits
If you bought 30 shares of ATNM before August 11, 2020, you'd have 1 share today.
| Execution Date | Split Amount |
|---|---|
| August 11, 2020 | 1-for-30 (Reverse Split) |
Cash Flow Statement
July 1, 2024 to September 30, 2024
| Metric | Value |
|---|---|
| Net Cash Flow From Investing Activities | $0 |
| Net Cash Flow, Continuing | $-7.37 Million |
| Net Cash Flow From Investing Activities, Continuing | $0 |
| Net Cash Flow From Operating Activities | $-11.97 Million |
| Net Cash Flow | $-7.37 Million |
| Net Cash Flow From Financing Activities, Continuing | $4.60 Million |
Income Statement
July 1, 2024 to September 30, 2024
| Metric | Value |
|---|---|
| Research and Development | $9.77 Million |
| Net Income/Loss Available To Common Stockholders, Basic | $-11.57 Million |
| Operating Expenses | $12.60 Million |
| Net Income/Loss Attributable To Noncontrolling Interest | $0 |
| Revenues | $0 |
| Depreciation and Amortization | $202,000 |
Comprehensive Income
July 1, 2024 to September 30, 2024
| Metric | Value |
|---|---|
| Comprehensive Income/Loss | $-11.57 Million |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0 |
| Comprehensive Income/Loss Attributable To Parent | $-11.57 Million |
| Other Comprehensive Income/Loss | $0 |
Balance Sheet
July 1, 2024 to September 30, 2024
| Metric | Value |
|---|---|
| Liabilities And Equity | $82.11 Million |
| Equity Attributable To Parent | $38.21 Million |
| Noncurrent Assets | $2.59 Million |
| Equity | $38.21 Million |
| Current Liabilities | $7.75 Million |
| Other Non-current Assets | $2.18 Million |
Historical Dividends
| Announcement Date | Payment Date | Record Date | Amount | Frequency |
|---|---|---|---|---|
| No historical dividends | ||||
Recent Headlines From The Web
Latest news, press releases, and media coverage about ATNM from trusted financial sources
â“’ 2025 Financhle. All Rights Reserved.